In this installment of BenchTalk, we take a look at how well antibodies are validated today and what you should be concerned about when selecting different antibodies for your research. Through interviews with David Rimm, professor of pathology at Yale University, and Andrew Bradbury, a staff member at Los Alamos National Lab, the need for proper antibody validation and the potential impact on the research community when antibodies are not properly validated are discussed.
For additional information on antibody validation, take a look at the 2010 review article from David Rimm and colleagues detailing a pipeline for proper antibody validation as well as this recent news article highlighting the impact of improper validation on basic research.
Podcast Date: November 26 2013 Run Time:
Next Generation Model Organisms: Benchtalk, Episode 4 New York, NY
Genome Editing Revolution: Benchtalk, Episode 3 New York, NY
Connectomics: Promises and Challenges | BenchTalk, Episode 2
BenchTalk, Episode 1: AGBT 2012 Round-up New York, NY
BioTalk: Emerging technologies in stem cell biology New York, NY
BioTalk: The Tet system and gene therapy New York, NY